Przejdź do zawartości
Merck

[Cefuroxime axetil, a new oral cephalosporin for treating infections of the ORL field: clinical synthesis].

Revue de laryngologie - otologie - rhinologie (1990-01-01)
J F Westphal
ABSTRAKT

Cefuroxime axetil (C.A.E.) is a broad spectrum cephalosporin, suitable for oral route. Its antibacterial activity includes all the pathogens usually responsible for E.N.T. infection, with low M.I.C.'s: H. influenzae, S. pneumoniae, S. aureus, S. pyogene. The stability of the drug against betalactamases, especially those produced by H. influenzae, associated with good bio availability (50%) and tissue penetration (30%) account for the potent in vivo bactericidal activity and clinical efficacy of cefuroxime axetil. More than 1,000 patients had been enrolled in controlled clinical trials: the success rates yielded by C.A.E. were 98%, 96% and 91%, respectively for pharingitis/tonsilitis, otitis media and acute sinusitis. C.A.E. is at least as effective as amoxycillin/clavulanic acid and safety appears to be better.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Cefuroxime, VETRANAL®, analytical standard
SKU
Gabaryty przesyłki
Dostępność
Cena netto
Ilość
Cefuroxime Axetil, European Pharmacopoeia (EP) Reference Standard
SKU
Gabaryty przesyłki
Dostępność
Cena netto
Ilość
USP
Cefuroxime Axetil, United States Pharmacopeia (USP) Reference Standard
SKU
Gabaryty przesyłki
Dostępność
Cena netto
Ilość